IGF2R Monoclonal Antibody (MEM-238), Invitrogen™

Description

• This antibody recognizes an epitope between domains 2 and 5 of CD222 (IGF2 receptor), a ubiquitously expressed 250 kDa multifunctional type I transmembrane protein
• The majority of CD222 is found in the late endosomal/prelysosomal compartment, 5-10% in the plasma membrane and the truncated (220 kDa) form of CD222 is present in human and bovine serum
• Western blot should be performed under non-reducing conditions
• Lysosomal enzymes containing one or two mannose 6-phosphate (man6P) moieties are moved about in the cell by two distinct but interconnected cycles by means of approximately 300 kDa cation independent mannose 6-phospate receptors (CI-MPR)
• The biosynthetic cycle refers to the MPR transport of newly synthesized lysosomal enzymes from the trans Golgi network to late endosomes or early lysosomes
• The endocytic cycle transports extracellular lysosomal enzymes from the plasma membrane via clathrin-coated vesicles to early endosomes
• The entire pool of MPRs cycles between these cellular compartments every 3 hours
• The steady state distribution of MPR's is predominantly within late endosomes, fewer in the trans Golgi network and approximately 10 % at cell surface
• In addition to its man6P binding activity, the MPR contains a separate binding site for the type II insulin-like growth factor and is capable of binding both man6P and IGF-II simultaneously
• An approximately 240 kDa soluble, truncated form, representing the extracellular domain of the protein, has also been found circulating in serum and is capable of binding both ligands.